The Four-Risk Framework for Evaluating Medtech Opportunities: Interview with SonoVascular CEO Daniel Estay

The Four-Risk Framework for Evaluating Medtech Opportunities: Interview with SonoVascular CEO Daniel Estay

From Medsider: Learn from Medtech and Healthtech Founders and CEOs by Scott Nelson

March 23, 2026 · 52 min

About this episode

Daniel Estay discusses evaluating medtech opportunities and the importance of relationships in the industry.

In this episode of Medsider Radio , we sat down with Daniel Estay , founder and CEO of SonoVascular . SonoVascular has developed a novel mechanical-pharmaco ultrasound facilitated thrombectomy system, SonoThrombectomy, that utilizes microbubble-mediated cavitation as a core enabling mechanism to remove blood clots more effectively. Dan has over 35 years of global medtech experience, including business development roles at Johnson & Johnson, where he worked on deals that helped create the world's first drug-eluting stent, and six years leading Abbott's cardiovascular device business across Asia-Pacific and Japan. He also serves as a Mentor-in-Residence at Duke University's New Ventures group. In this interview, Dan discusses how to evaluate whether a medtech opportunity is commercially viable beyond technical feasibility, how trust and long-standing relationships matter more than geography when selecting first-in-human sites, and why cap table strategy requires deliberate thinking from the earliest stages — including when to transition from convertible notes to priced rounds. Before we dive into the discussion, I wanted to mention a few things: First, if you’re into learning…

More episodes of Medsider: Learn from Medtech and Healthtech Founders and CEOs

Explore listener stats, chart rankings, contacts and more on the Medsider: Learn from Medtech and Healthtech Founders and CEOs podcast page.